American College of Cardiology/American Heart Association Task Force

American College of Cardiology/American Heart Association Task Force
Name	American College of Cardiology/American Heart Association Task Force
Formation	20th century
Type	Joint clinical guideline task force
Headquarters	United States
Fields	Cardiology, American Board of Internal Medicine, Cardiac surgery, Interventional cardiology

American College of Cardiology/American Heart Association Task Force is a joint expert panel convened by American College of Cardiology and American Heart Association to develop clinical practice guidelines for cardiovascular care. The Task Force synthesizes evidence to inform practice across settings influenced by institutions such as National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Its outputs affect policy, reimbursement, and clinical pathways used in hospitals like Mayo Clinic, Cleveland Clinic, and universities such as Johns Hopkins University and Harvard Medical School.

History and formation

The Task Force originated during collaborative efforts between American College of Cardiology and American Heart Association following landmark events like the rise of outcomes research at Dartmouth College and initiatives from National Heart, Lung, and Blood Institute. Early contributors included clinicians affiliated with Massachusetts General Hospital, UCSF Medical Center, and Mount Sinai Hospital, with influence from committees at World Health Organization, Royal College of Physicians, and European Society of Cardiology. Formation paralleled developments at American Medical Association and codification efforts influenced by reports from Institute of Medicine and The Joint Commission.

Mission and objectives

The Task Force aims to produce evidence-based guidance aligning standards employed by entities such as Centers for Medicare & Medicaid Services, American College of Physicians, and American Academy of Pediatrics. Objectives include standardizing care across systems like Kaiser Permanente and academic consortia at Stanford University School of Medicine, reducing variability noted in studies from Duke University School of Medicine, and translating randomized trial results from Framingham Heart Study cohorts and registries such as Get With The Guidelines. It seeks to inform clinicians at institutions including UCLA Health, University of Pennsylvania Health System, and professional societies like Society for Cardiovascular Angiography and Interventions.

Guideline development process

Guideline development follows methodologies advocated by bodies including GRADE Working Group, Cochrane Collaboration, and scholars from Yale University. Panels draw experts from specialties represented by American College of Cardiology, American Heart Association, Society of Thoracic Surgeons, American Association of Cardiovascular and Pulmonary Rehabilitation, and patient representatives modeled on initiatives from Patient-Centered Outcomes Research Institute. Processes incorporate systematic reviews produced by teams at Cleveland Clinic Foundation, meta-analyses referencing trials such as PARADIGM-HF, and subgroup analyses similar to those from SOLVD Trial investigators. Conflict of interest policies mirror standards used by National Academies of Sciences, Engineering, and Medicine and disclosures akin to Open Payments reporting.

Major clinical guidelines and publications

The Task Force has issued influential guidance on topics like acute coronary syndromes reflecting evidence from TIMI Study Group, hypertension aligning with trials conducted at British Medical Journal collaborators, and cholesterol management influenced by outcomes from PROVE-IT TIMI 22 and IMPRESS Trial investigators. Other major publications address heart failure with reference to COPERNICUS Trial, atrial fibrillation drawing on data from AFFIRM Trial, valvular heart disease paralleling work by PARTNER Trial investigators, and preventive cardiology incorporating findings from Women's Health Initiative and WHI. Guidance documents are cited in guideline compendia alongside those from European Society of Cardiology, National Institute for Health and Care Excellence, and the Canadian Cardiovascular Society.

Governance and organizational structure

Governance includes clinical leaders from American College of Cardiology and American Heart Association boards, with committee chairs often affiliated with Yale School of Medicine, Columbia University Irving Medical Center, Vanderbilt University Medical Center, and Emory University School of Medicine. Administrative oversight interacts with standards groups such as American National Standards Institute and accreditation stakeholders like Commission on Accreditation of Rehabilitation Facilities. Panels include methodologists from Brown University, statisticians linked to University of Michigan, and legal advisers versed in regulations from Department of Health and Human Services.

Collaboration and partnerships

The Task Force collaborates with academic centers including University of California, San Diego, University of Texas Southwestern Medical Center, and professional societies such as Heart Rhythm Society and Pediatric Cardiology Society. Partnerships span registries like STS National Database, research networks such as ClinicalTrials.gov submitters, and international organizations including World Heart Federation and International Society for Heart and Lung Transplantation. Joint statements have been coordinated with public health actors like American Public Health Association and philanthropic funders such as Bill & Melinda Gates Foundation in global cardiovascular initiatives.

Impact, critiques, and controversies

The Task Force's guidelines have shaped practice at health systems like Intermountain Healthcare and informed payment policies at Centers for Medicare & Medicaid Services; however, they have faced critiques similar to those directed at guideline processes at National Institute for Health and Care Excellence, including debates over evidence thresholds seen in controversies around hypertension guideline changes, and disputes echoing critiques of industry influence noted in investigations involving Pharmaceutical Research and Manufacturers of America. Methodological debates involve comparisons to approaches used by Cochrane Collaboration and editorial commentary from journals such as The Lancet and New England Journal of Medicine. Calls for transparency and reproducibility reference reforms proposed by Institute of Medicine and watchdogs like ProPublica.

Category:Cardiology organizations